Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 2, 2008, Pages 490-496

  Tsui, Janet Y ^a   Dalgard, Clifton ^a   Van Quill, Kurtis R ^a   Lee, Linda ^a   Grossniklaus, Hans E ^b   Edelhauser, Henry F ^b   O'Brien, Joan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN GLUE; LUTEINIZING HORMONE BETA SUBUNIT; TOPOTECAN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; ENZYME INHIBITOR; LUTEINIZING HORMONE; VIRUS T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFECT; EYE TOXICITY; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; TUMOR VOLUME; WILD TYPE; ANIMAL; CELL CULTURE; CELL CYCLE; CONJUNCTIVA; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENETICS; INJECTION; PATHOLOGY; RETINA TUMOR; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CONJUNCTIVA; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; FIBRIN TISSUE ADHESIVE; INJECTIONS; LUTEINIZING HORMONE; MICE; MICE, TRANSGENIC; RETINAL NEOPLASMS; RETINOBLASTOMA; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 40649113410     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-0653     Document Type: Article

References (41)

1. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323:643-646.
2. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science. 1987;235:1394-1399.
3. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA. 1997;278:1262-1267.
4. Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol. 1998;116:1209-1212.
5. Li SK, Molokhia SA, Jeong EK. Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm Res. 2004;21:2175-2184.
6. Robinson MR, Lee SS, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82:479-487.
7. Ghate D, Brooks W, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007;48:2230-2237.
8. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano-and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003;44:1192-1201.
9. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004;21:1797-1804.
10. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106:1947-1950.
11. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121:1120-1124.
12. Kiratli H, Kocabeyoglu S, Bilgic S. Severe pseudo-preseptal cellulitis following sub-Tenon carboplatin injection for intraocular retinoblastoma. J AAPOS. 2007;11:404-405.
13. Schmack I, Hubbard GB, Kang SJ, Aaberg TM Jr, Grossniklaus HE. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142:310-315.
14. Simpson AE, Gilbert JA, Rudnick DE, Geroski DH, Aaberg TM Jr, Edelhauser HF. Transscleral diffusion of carboplatin: an in vitro and in vivo study. Arch Ophthalmol. 2002;120:1069-1074.
15. Pardue MT, Hejny C, Gilbert JA, Phillips MJ, Geroski DH, Edelhauser HF. Retinal function after subconjunctival injection of carboplatin in fibrin sealant. Retina. 2004;24:776-782.
16. Van Quill KR, Dioguardi PK, Tong CT, et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology. 2005;112:1151-1158.
17. Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G. Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells. Tumour Biol. 1998;19:356-363.
18. Calvaruso G, Carabillo M, Giuliano M, et al. Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan. Int J Oncol. 2001;18:1233-1237.
19. Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res. 2005;11:7569-7578.
20. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006;444:61-66.
21. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1998;20:315-318.
22. Frangoul H, Ames MM, Mosher RB, et al. Phase I studyoftopotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin Cancer Res. 1999;5:3956-3962.
23. Chantada GL, Fandino AC, Casak SJ, Mato G, Manzitti J, Schvartzman E. Activity of topotecan in retinoblastoma. Ophthalmic Genet. 2004;25:37-43.
24. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
25. Bernard R. The treatment of outliers. In: Fundamentals of Biostatistics. 5th ed. Belmont, CA: Duxbury Press; 2005;300-305.
26. Carcaboso AM, Bramuglia GF, Chantada GL, et al. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci. 2007;48:3761-3767.
27. Maurice DM, Polgar J. Diffusion across the sclera. Exp Eye Res. 1977;25:577-582.
28. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
29. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479-1488.
30. Edwards A, Prausnitz M. Fiber matrix model of sclera and corneal stroma for drug delivery to the eye. AIChE J. 1998;44:214-225.
31. Cruysberg LP, Nuijts RM, Geroski DH, Koole LH, Hendrikse F, Edelhauser HF. In vitro human scleral permeability of fluorescein, dexamethasone- fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J Ocul Pharmacol Ther. 2002;18:559-569.
32. Rudnick DE, Noonan JS, Geroski DH, Prausnitz MR, Edelhauser HF. The effect of intraocular pressure on human and rabbit scleral permeability. Invest Ophthalmol Vis Sci. 1999;40:3054-3058.
33. Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol. 1999;104:175-183.
34. Mi Z, Malak H, Burke TG. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry. 1995;34:13722-13728.
35. Oguri S, Sakakibara T, Mase H, et al. Clinical pharmacokinetics of carboplatin. J Clin Pharmacol. 1988;28:208-215.
36. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138:1046-1048.
37. Thomas ER, Wang J, Ege E, Madsen R, Hainsworth DP. Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol. 2006;142:860-861.
38. Rudolph AM, Hoffman JIE, Rudolph CD. Rudolph's Pediatrics. 19th ed. Norwalk, CT: Appleton & Lange; 1991.
39. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
40. Cliby WA, Lewis KA, Lilly KK, Kaufmann SH. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem. 2002;277:1599-1606.
41. Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002;20:88-95.